Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epacadostat - Incyte Corporation

Next Previous
X
Search
Drug Profile

Epacadostat - Incyte Corporation

Alternative Names: INCB-024360; INCB-24360

Latest Information Update: 26 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Aduro BioTech; Bristol-Myers Squibb; Columbia University; IMV; Incyte Corporation; MedImmune; Merck AG; Merck Sharp & Dohme; National Cancer Institute (USA); Sidney Kimmel Cancer Center; Stanford University; Washington University School of Medicine
  • Class Antineoplastics; Halogenated hydrocarbons; Nitroso compounds; Oxadiazoles; Small molecules; Sulfonamides
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Phase II Endometrial cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Solid tumours
  • Phase I/II Cancer; Colorectal cancer; Prostate cancer; Rectal cancer

Most Recent Events

  • 08 Oct 2024 National Cancer Institute completes a QuEST1 phase-I/II clinical trial in Prostate cancer (Combination therapy, Hormone-refractory, Late-stage disease) in the USA (PO) (NCT03493945)
  • 08 Oct 2024 National Cancer Institute completes the QuEST1 phase I/II trial for Solid tumours (Combination therapy, Metastatic disease, Second line therapy or greater) in USA (PO)(NCT03493945)
  • 13 Sep 2024 Efficacy and adverse event data from the phase I/II QuEST1 trial in Prostate cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top